Solid Biosciences Shares Updates on Inspire Duchenne Clinical Trial of SGT-003
Solid Biosciences, a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases that acquired UF startup AavantiBio, shared updates on the INSPIRE DUCHENNE clinical trial for their next-generation AAV micro-dystrophin gene therapy candidate, SGT-003, for the treatment of Duchenne.
